GGrantIndex
← Leaderboards

Juan J. L. Lertora

Tulane University Of Louisiana

Google Scholar ↗PubMed ↗ORCID ↗
$4,837,795
Attributed
$4,837,795
Total exposure
32
Grants
1
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $12.7K · FY2005–06
$20K$15K$10K$5K$0
'05
'06

Funding mix

By agency

NIH$6,098,737 · 33

By mechanism

U01$5,916,039 · 10
M01$182,698 · 23

Top collaborators

No co-investigators on record.

Most similar at Tulane University Of Louisiana

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject”

Research focus

Human SubjectClinical ResearchAids TherapyHuman Therapy EvaluationHiv InfectionsAidsClinical Trial Phase ICombination ChemotherapyAntiaids AgentCooperative StudyHuman Immunodeficiency Virus 1Drug Screening /EvaluationProtease InhibitorPharmacokineticsZidovudineVirus LoadVirus ReplicationBiomarkerImmunotherapyReverse Transcriptase InhibitorsPathologic ProcessComorbidityFemaleCytokine

Grant awards (68)

CLINICAL EVALUATION OF FLOWABLE COMPOSITE RESIN$1,166
M01 · FY2006 · RR · contact PI
TRIAL OF TWO POTENT, SIMPLIFIED REGIMENS UTILIZING A PROTEASE INHIBITOR-SPARING$11,075
M01 · FY2005 · RR
QUALITY ASSESSMENT STUDY FOR VIABLE PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC)$1,640
M01 · FY2005 · RR
Trial of Two Potent, Simplified Regimens$25,993
M01 · FY2004 · RR
Quality Assessment Study for PBMCs$5,053
M01 · FY2004 · RR
Study of Prolongation of Virologic Success and Options From Failure in HIV$3,611
M01 · FY2004 · RR
AIDS CLINICAL TRIALS UNIT$285,956
U01 · FY2002 · AI
NEUROLOGY AGENDA$172,411
U01 · FY2002 · AI
COMPLICATIONS OF HIV DISEASE AGENDA$172,411
U01 · FY2002 · AI
HIV DISEASE RESEARCH AGENDA$172,411
U01 · FY2002 · AI
CORE--ADVANCED TECHNOLOGY LABORATORIES$172,411
U01 · FY2002 · AI
OUTREACH AGENDA$172,411
U01 · FY2002 · AI
OUTCOMES COMMITTEE AGENDA$172,411
U01 · FY2002 · AI
WOMEN'S HEALTH AGENDA$172,411
U01 · FY2002 · AI
PHARMACOLOGY AGENDA$172,411
U01 · FY2002 · AI
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA$172,411
U01 · FY2002 · AI
AIDS CLINICAL TRIALS UNIT$318,973
U01 · FY2001 · AI
CORE--ADVANCED TECHNOLOGY LABORATORIES$172,411
U01 · FY2001 · AI
OUTREACH AGENDA$172,411
U01 · FY2001 · AI
OUTCOMES COMMITTEE AGENDA$172,411
U01 · FY2001 · AI
WOMEN'S HEALTH AGENDA$172,411
U01 · FY2001 · AI
PHARMACOLOGY AGENDA$172,411
U01 · FY2001 · AI
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA$172,411
U01 · FY2001 · AI
NEUROLOGY AGENDA$172,411
U01 · FY2001 · AI
COMPLICATIONS OF HIV DISEASE AGENDA$172,411
U01 · FY2001 · AI
HIV DISEASE RESEARCH AGENDA$172,411
U01 · FY2001 · AI
ACTG 398:AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN HI$0
M01 · FY2001 · RR
ACTG 343--TRIAL OF 3 MAINTENANCE REGIMENS FOR HIV+ SUBJECTS$0
M01 · FY2001 · RR
ACTG 328--INTERMITTENT RECOMBINANT HUMAN IL2 + HAART VS HAART ALONE--AIDS$0
M01 · FY2001 · RR
ACTG 368--TRIAL OF 1592U89 IN COMBINATION W/ IDV AND DMP-266 IN HIV+$0
M01 · FY2001 · RR
ACTG 372:STUDY OF PROLONGATION OF VIROLOGIC SUCCESS &OPTIONS FROM FA$0
M01 · FY2001 · RR
ACTG 388:TRIAL OF EFAVIRENZ OR NELFINAVIR IN COMBINATION W/ 3TC/ZDV &$0
M01 · FY2001 · RR
PROTEASE INHIBITOR/NON-NUCLEOSIDE RT INHIBITOR$0
M01 · FY2001 · RR
PHASE II STUDY OF HYDROXYUREA IN HIV INFECTION$0
M01 · FY2001 · RR
INTERLEUKIN 2 PLUS HIGHLY ACTIVE ANTIRETROVIRAL THERAPY$0
M01 · FY2001 · RR
SALVAGE ANTIRETROVIRAL THERAPIES$0
M01 · FY2001 · RR
PROTEIN SUPPLEMENTS IN HIV+ SUBJECTS WITH WEIGHT LOSS$0
M01 · FY2001 · RR
PROTEASE INHIBITORS AND LIPID LOWERING AGENTS$0
M01 · FY2001 · RR
ONCOGENIC VIRAL PATHOGENESIS/CANCER RISK FACTORS IN AIDS$0
M01 · FY2001 · RR
AIDS CLINICAL TRIALS UNIT$656,013
U01 · FY2000 · AI
CORE--ADVANCED TECHNOLOGY LABORATORIES$172,411
U01 · FY2000 · AI
OUTREACH AGENDA$172,411
U01 · FY2000 · AI
OUTCOMES COMMITTEE AGENDA$172,411
U01 · FY2000 · AI
WOMEN'S HEALTH AGENDA$172,411
U01 · FY2000 · AI
PHARMACOLOGY AGENDA$172,411
U01 · FY2000 · AI
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA$172,411
U01 · FY2000 · AI
NEUROLOGY AGENDA$172,411
U01 · FY2000 · AI
COMPLICATIONS OF HIV DISEASE AGENDA$172,411
U01 · FY2000 · AI
HIV DISEASE RESEARCH AGENDA$172,411
U01 · FY2000 · AI
ACTG 343--TRIAL OF 3 MAINTENANCE REGIMENS FOR HIV+ SUBJECTS$11,180
M01 · FY2000 · RR
ACTG 313--MEGESTROL ACETATE/TESTOSTERONE ENANTHATE COMBINATION VS ALONE IN AIDS$11,180
M01 · FY2000 · RR
ACTG 248--PHASE II STUDY OF IL 2 BY SUBCUTANEOUS INJECTION OF HIV/ANTIRETROVIRAL$11,180
M01 · FY2000 · RR
ACTG 383:DYNAMICS OF HEPATITIS C IN PATIENTS INFECTED W/ HEPATITIS C$11,180
M01 · FY2000 · RR
ACTG 372:STUDY OF PROLONGATION OF VIROLOGIC SUCCESS &OPTIONS FROM FA$11,180
M01 · FY2000 · RR
ACTG 320--PHASE III STUDY OF INDINAVIR WITH ZDV AND 3TC IN SUBJECTS WITH HIV$11,180
M01 · FY2000 · RR
ACTG 309:PHARMACOKINETICS OF ANTITUBERCULOSIS AGENTS IN HIV INFECTED$11,180
M01 · FY2000 · RR
ACTG 359--ACTIVITY OF SOFT GELATIN CAPSULE SAQUINAVIR IN COMBINATION--HIV+$11,180
M01 · FY2000 · RR
ACTG 368--TRIAL OF 1592U89 IN COMBINATION W/ IDV AND DMP-266 IN HIV+$11,180
M01 · FY2000 · RR
ACTG 328--INTERMITTENT RECOMBINANT HUMAN IL2 + HAART VS HAART ALONE--AIDS$11,180
M01 · FY2000 · RR
ACTG 398:AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN HI$11,180
M01 · FY2000 · RR
ACTG 388:TRIAL OF EFAVIRENZ OR NELFINAVIR IN COMBINATION W/ 3TC/ZDV &$11,180
M01 · FY2000 · RR
PROTEIN SUPPLEMENTS IN HIV+ SUBJECTS WITH WEIGHT LOSS$0
M01 · FY2000 · RR
SALVAGE ANTIRETROVIRAL THERAPIES$0
M01 · FY2000 · RR
INTERLEUKIN 2 PLUS HIGHLY ACTIVE ANTIRETROVIRAL THERAPY$0
M01 · FY2000 · RR
PHASE II STUDY OF HYDROXYUREA IN HIV INFECTION$0
M01 · FY2000 · RR
PROTEASE INHIBITORS AND LIPID LOWERING AGENTS$0
M01 · FY2000 · RR
ONCOGENIC VIRAL PATHOGENESIS/CANCER RISK FACTORS IN AIDS$0
M01 · FY2000 · RR
PROTEASE INHIBITOR/NON-NUCLEOSIDE RT INHIBITOR$0
M01 · FY2000 · RR